A 1 adenosine receptor antagonists

Details A 1 adenosine receptor antagonists A 1 adenosine receptor antagonists

2011-03-08

2011-03-08

Berch, Mark L (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen bonded directly to ring carbon of the purine ring...

C544S272000

Reexamination Certificate

active

07902360

ABSTRACT:
wherein R3is Alk14ArR16, and wherein Alk14is C1-8straight or branched alkylene or alkenylene.The present invention provides novel adenosine receptor antagonists, more particularly, A1adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1adenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel A1adenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating A1adenosine receptor related disorders comprising administering an A1adenosine receptor antagonist of formula I are also disclosed. The novel A1adenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods.

REFERENCES:
patent: 2840559 (1958-06-01), Krantz et al.
patent: 2887486 (1959-05-01), Leake et al.
patent: 3031451 (1962-04-01), Schlesinger et al.
patent: 3309271 (1967-03-01), Georges et al.
patent: 3317533 (1967-05-01), De Ridder
patent: 3961060 (1976-06-01), Fuxe
patent: 4092417 (1978-05-01), Credner et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4378359 (1983-03-01), Chiodoni et al.
patent: 4548818 (1985-10-01), Kjellin et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4622324 (1986-11-01), Klessing et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4772607 (1988-09-01), Badger et al.
patent: 4868186 (1989-09-01), Franzone et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5032593 (1991-07-01), Rzeszotarski et al.
patent: 5066655 (1991-11-01), Olsson
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5248770 (1993-09-01), Jacobson et al.
patent: 5256650 (1993-10-01), Peet et al.
patent: 5290782 (1994-03-01), Suzuki et al.
patent: 5296463 (1994-03-01), Lee et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5314890 (1994-05-01), Agostini et al.
patent: 5340813 (1994-08-01), Klein et al.
patent: 5395836 (1995-03-01), Shimada et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5447933 (1995-09-01), Suzuki et al.
patent: 5504090 (1996-04-01), Neely
patent: 5532368 (1996-07-01), Kufner-Muhl et al.
patent: 5543415 (1996-08-01), Suzuki et al.
patent: 5545627 (1996-08-01), Jacobson et al.
patent: 5714494 (1998-02-01), Connell et al.
patent: 5719279 (1998-02-01), Kufner-Muhl
patent: 5733916 (1998-03-01), Neely
patent: 5739331 (1998-04-01), Thyrion et al.
patent: 5786360 (1998-07-01), Neely
patent: 5932557 (1999-08-01), Mustafa et al.
patent: 6001842 (1999-12-01), Neely
patent: 6117445 (2000-09-01), Neely
patent: 6187780 (2001-02-01), Blech et al.
patent: 6489332 (2002-12-01), Neely
patent: 6919337 (2005-07-01), Bhalay et al.
patent: 7135475 (2006-11-01), Dunten et al.
patent: 7247639 (2007-07-01), Wilson et al.
patent: 7423041 (2008-09-01), Wilson et al.
patent: 2002/0058667 (2002-05-01), Castelhano et al.
patent: 2002/0058669 (2002-05-01), Van Helden et al.
patent: 2002/0082269 (2002-06-01), Neely
patent: 2002/0111333 (2002-08-01), Lin et al.
patent: 2003/0114469 (2003-06-01), Cohen
patent: 2003/0212082 (2003-11-01), Linden et al.
patent: 2004/0014766 (2004-01-01), Dunten et al.
patent: 2004/0110774 (2004-06-01), Wilson
patent: 2004/0259889 (2004-12-01), Smits et al.
patent: 2005/0119258 (2005-06-01), Wilson et al.
patent: 2005/0222179 (2005-10-01), Ensinger et al.
patent: 2005/0261316 (2005-11-01), Kalla et al.
patent: 2006/0135467 (2006-06-01), Zablocki et al.
patent: 2006/0205745 (2006-09-01), Kuroda et al.
patent: 2007/0274910 (2007-11-01), Wilson et al.
patent: 2008/0293705 (2008-11-01), Wilson et al.
patent: 2009/0068101 (2009-03-01), Wilson et al.
patent: 636 828 (1964-03-01), None
patent: 1 245 383 (1967-07-01), None
patent: 26 59 241 (1978-07-01), None
patent: 0 501 379 (1992-09-01), None
patent: 0 503 563 (1992-09-01), None
patent: 0 764 647 (1997-03-01), None
patent: 2 483 922 (1981-11-01), None
patent: 947495 (1964-01-01), None
patent: 9216883 (1997-08-01), None
patent: WO 98/03507 (1998-01-01), None
patent: WO 99/67239 (1999-12-01), None
patent: WO 01/34610 (2001-05-01), None
patent: WO 03/028730 (2003-04-01), None
patent: WO 03/028730 (2003-10-01), None
patent: WO 03103675 (2003-12-01), None
patent: WO 2004/074247 (2004-09-01), None
patent: WO 2004/110379 (2004-12-01), None
Abbracchio, M.P. and F. Cattabeni, “Selective Activity of Bamifylline on Adenosine A1-Receptors in Rat Brain,”Pharmacological Research Communications, 1987, pp. 537-545, vol. 19(8).
Ali, et al., “Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Edenosine A1receptor,”The Journal of Pharmacology and Experimental Therapeutics, 1993, pp. 1328-1334, vol. 268(3).
Angulo, et al., “A1Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation,”Brain Pathol. 2003, pp. 440-451.
Aslanian, et al., “Cardiovascular and Pulmonary Diseases,”Annual Reports in Medicinal Chemistry, 2001, pp. 32-40, vol. 36(II), Academic Press, San Diego, CA.
Ball, et al., “Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma,”Am. J. Pharmocogenomics, 2003, pp. 97-106, vol. 3(2).
Beauglehole, A.R., et al., “Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A1-Adenosine Receptor,”J. Med. Chem., 2000, pp. 4973-4980, vol. 43.
Beauglehole, A.R., et al., “New Irreversible Adenosine A1Antagonists Based on FSCPX,”Bioorganic and Medicinal Chemist Letters, 2002, pp. 3179-3182, vol. 12.
Belardinelli, L., et al., “1, 3-Dipropyl-8-[2-(5,6-Epoxy)Norbomyl]Xanthine, a Potent Specific and Selective A1Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT1MF-2 Cells,”The Journal of Pharmacology and Experimental Therapeutics, 1995, pp. 1167-1176, vol. 276(2).
Belliardo, F. and C. Lucarelli, “Micro-Scale Liquid Chromatographic Method for the Determination of Bamifylline and its Major Metabolite in Human Plasma,”Journal of Chromatography, 1990, pp. 305-309, vol. 535.
Berti, et al., “Pharmacological Activity of Bamifylline on Lung Anaphylaxis: In Vitro Studies,”Pharmacological Research, 1990, vol. 22(2).
Burke, S.D., and R. L. Danheiser, “Oxidizing and Reducing Agents,”Handbook of Reagents for Organic Synthesis, John Wiley & Sons, 1999, pp. 170-173.
Carlucci, G., et al., “Determination of Bamifylline Hydrochloride Impurities in Bulk Material and Pharmaceutical Forms Using Liquid Chromatograpy with Ultraviolet Detection,”Journal of Pharmaceutical&Biomedical Analysis, 1990, pp. 1067-1069, vol. 8.
CAS Client Services Report dated Nov. 8, 2006.
Cronstein, et al., “Neutrophil Adherence to Endothelium is Enhanced Via Adenosine A1Receptors and Inhibited Via Adenosine A2Receptors,”The Journal of Immunology, 1992, pp. 2201-2206, vol. 148.
Cronstein, et al., “The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A1 and A2 Receptors that Promote Chemotaxis and Inhibit O2Generation, Respectively,”J. Clinic. Invest., 1990, pp. 1150-1157, vol. 85.
Dar, M.S. et al., “Acute Ethanol / Cannabinoid-Induced Ataxia and Its Antagonism by Oral/Systemic/Intracerebellar A1Adenosine Receptor Antisense in Mice,”Brain Research, 2002, pp. 53-60, vol. 957.
Foley, L.H. et al., “Modified 3-Alkyl-1, 8-dibenzylxanthines as GTP-Competitive Inhibitors of Phosphoenolpyruvate Carboxykinase,”Bioorganic&Medicinal Chemistry Letters, 2003, pp. 3607-3610, vol. 13.
Forman, et al., “Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil C

Affiliated with

Also associated with

Rating

A 1 adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A 1 adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A 1 adenosine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621540